BRPI0710185B8 - anticorpo contra receptor de fator de crescimento i semelhante à insulina - Google Patents

anticorpo contra receptor de fator de crescimento i semelhante à insulina

Info

Publication number
BRPI0710185B8
BRPI0710185B8 BRPI0710185A BRPI0710185A BRPI0710185B8 BR PI0710185 B8 BRPI0710185 B8 BR PI0710185B8 BR PI0710185 A BRPI0710185 A BR PI0710185A BR PI0710185 A BRPI0710185 A BR PI0710185A BR PI0710185 B8 BRPI0710185 B8 BR PI0710185B8
Authority
BR
Brazil
Prior art keywords
antibody
receptor
growth factor
amount
insulin
Prior art date
Application number
BRPI0710185A
Other languages
English (en)
Portuguese (pt)
Inventor
Reusch Dietmar
Kuenkele Klaus-Peter
Schumacher Ralf
Hansen Silke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0710185(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0710185A2 publication Critical patent/BRPI0710185A2/pt
Publication of BRPI0710185A8 publication Critical patent/BRPI0710185A8/pt
Publication of BRPI0710185B1 publication Critical patent/BRPI0710185B1/pt
Publication of BRPI0710185B8 publication Critical patent/BRPI0710185B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0710185A 2006-04-11 2007-04-10 anticorpo contra receptor de fator de crescimento i semelhante à insulina BRPI0710185B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
EP06007571.0 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (4)

Publication Number Publication Date
BRPI0710185A2 BRPI0710185A2 (pt) 2011-08-09
BRPI0710185A8 BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B1 BRPI0710185B1 (pt) 2020-01-14
BRPI0710185B8 true BRPI0710185B8 (pt) 2021-05-25

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710185A BRPI0710185B8 (pt) 2006-04-11 2007-04-10 anticorpo contra receptor de fator de crescimento i semelhante à insulina

Country Status (20)

Country Link
US (1) US20080014203A1 (enExample)
EP (2) EP2007810B1 (enExample)
JP (1) JP4718634B2 (enExample)
KR (2) KR101276513B1 (enExample)
CN (1) CN101421305B (enExample)
AR (1) AR060592A1 (enExample)
AU (1) AU2007236199B2 (enExample)
BR (1) BRPI0710185B8 (enExample)
CA (2) CA3081707A1 (enExample)
CR (1) CR10301A (enExample)
EC (1) ECSP088816A (enExample)
ES (1) ES2403075T3 (enExample)
IL (1) IL194397A (enExample)
MX (1) MX2008012950A (enExample)
NO (1) NO20084082L (enExample)
NZ (1) NZ571414A (enExample)
RU (1) RU2541765C2 (enExample)
UA (1) UA95284C2 (enExample)
WO (1) WO2007115814A2 (enExample)
ZA (1) ZA200808597B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
JP5921433B2 (ja) 2009-07-24 2016-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 攪拌システム
CA2774953A1 (en) 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
KR101593766B1 (ko) 2010-11-05 2016-02-15 에프. 호프만-라 로슈 아게 혼합식 크로마토그래피에 의한 최적화된 항체 포획 방법
CN110229235A (zh) 2011-06-22 2019-09-13 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
CA2889788A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
EP1613658B1 (en) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
EP2007810B1 (en) 2013-02-13
AU2007236199B2 (en) 2013-07-25
ZA200808597B (en) 2009-11-25
UA95284C2 (ru) 2011-07-25
NO20084082L (no) 2008-11-06
KR20080113233A (ko) 2008-12-29
WO2007115814A2 (en) 2007-10-18
CN101421305B (zh) 2013-05-15
CR10301A (es) 2008-10-29
RU2008144290A (ru) 2010-05-20
ECSP088816A (es) 2008-11-27
AU2007236199A1 (en) 2007-10-18
CN101421305A (zh) 2009-04-29
CA2647181A1 (en) 2007-10-18
WO2007115814A3 (en) 2008-01-10
EP2363417A1 (en) 2011-09-07
IL194397A (en) 2014-04-30
BRPI0710185B1 (pt) 2020-01-14
MX2008012950A (es) 2008-10-15
RU2541765C2 (ru) 2015-02-20
ES2403075T3 (es) 2013-05-13
EP2007810A2 (en) 2008-12-31
JP4718634B2 (ja) 2011-07-06
US20080014203A1 (en) 2008-01-17
CA2647181C (en) 2020-08-11
IL194397A0 (en) 2011-08-01
AR060592A1 (es) 2008-07-02
BRPI0710185A8 (pt) 2019-01-22
BRPI0710185A2 (pt) 2011-08-09
KR101276513B1 (ko) 2013-06-21
NZ571414A (en) 2011-12-22
KR20120028396A (ko) 2012-03-22
JP2009533367A (ja) 2009-09-17
CA3081707A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
BRPI0710185B8 (pt) anticorpo contra receptor de fator de crescimento i semelhante à insulina
BRPI0709960B8 (pt) anticorpo monoclonal do tipo igg1 ou igg3 humana glicosilado, seu uso e método de produção e composição farmacêutica
O'Donnell et al. A calcineurin-dependent switch controls the trafficking function of α-arrestin Aly1/Art6
BRPI0815331A2 (pt) composição farmacêutica compreendendo um derivado de benzeno glucopiranosila substituída
BRPI0507594A (pt) polipetìdeos hìbridos com propriedades selecionáveis
BR112014007687A8 (pt) Composiçâo farmacêutica de anticorpos para eliminação de antígenos no plasma
HN2009000784A (es) Dihidropirazolonas sustituidas
BR112014013412A2 (pt) anticorpos para o receptor 3 do fator de crescimento epidérmico (her3)
BRPI0606992A2 (pt) análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
CL2009000586A1 (es) Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
BR112017016200A8 (pt) Método para produzir hidrogéis conjugando módulo de alta elasticidade e absorvência
BRPI0519507A2 (pt) uso de fàrmula lactente com teor de proteÍna reduzido
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CR20150097A (es) Composición inmunogénica
ECSP11010760A (es) Derivados de quinoxalindiona
BRPI0600199A (pt) usos de ácido pinolênico ou um seu derivado e de uma composição
BR112016014042A2 (pt) composições e métodos para tratar deposição de tecido adiposo
CO6561811A2 (es) Composiciones de etanol
BR102017016334A8 (pt) Produto de condensação de 1-amino-2-propanol e formaldeído e o uso do mesmo para a redução da quantidade de sulfeto de hidrogênio em líquidos e gases
BR112012014564A2 (pt) "método de combate e controle de pragas"
Qsaib et al. Changes in levels of hydrogen peroxide and phenolic compounds in grapevine latent buds during the annual cycle
BR112014009273A8 (pt) espelho
Ouellette Defensins in enteric mucosal immunity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF